TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: change in self-control over neuronal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response rate to NKX101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of hyperbilirubinemia within the first seven days of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biobehavioral Factors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Procedural success (removal of occlusion and restoration of blood flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Respiratory recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intestinal transit recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maternal Evoked Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in time values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in repetitions values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune system function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune and inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BOLD fMRI signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Therapeutic Responder at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Device/Procedure Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change From Baseline in Total Hip Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Detection of pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tanner Stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive values of age-based PSA thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate After 2 Cycles of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate After 3 Cycles of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Ability to Collect Stem Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Function Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in 6 Minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The number of subjects with dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: The number of subjects who have at least one serious adverse event related to the study
Endpoint domain: Adverse events/effects
Primary endpoint: Survival free of grade >= 3 toxicity
Endpoint domain: Mortality/survival
Primary endpoint: Memory for Faces Delayed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidental Face Memory (IFM) Event-Related Potential (ERP) Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities-Specific Balance Confidence scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of Participants Receiving Additional Surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Histological improvement of alcoholic hepatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Rate of serious adverse cardiovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of Inflammatory Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rotator Cuff Tear Confirmation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: First Occurrence of a Major Cardiovascular Event (MCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pathological near complete or complete tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Impaired level of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Impaired content of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Death Due to Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: Overall Clinical Response Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of capecitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of BMS-247550
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Mayo Risk Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response (CR, mCR and Cri)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zone of keratinized gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression free survival at one year
Endpoint domain: Mortality/survival
Primary endpoint: Total number of AF cases newly diagnosed
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients assigned to anticoagulation therapy for the first time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to anticoagulation therapy for warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in accuracy in recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity Score for 28-joint Counts (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-free
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects exhibiting sero-responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stress sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 18 Week Progression-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients requiring endotracheal intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Pure Tone Average PTA4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematological changes in newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Biomarker Endpoint (NFL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biomarker Endpoint (Inflammation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biomarker Endpoint (Neurogenesis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Zinc protoporphyrin blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of Oxaliplatin, Irinotecan, and Capecitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceptions of clarity and ease of response
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Feasibility of an injectable naltrexone study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Activity of FOLFOX regimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: FSHD Clinical Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ventilator pressure support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the amount of gingival display
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteointegration of V-Blast surface implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: disease specific survival (DSS)
Endpoint domain: Mortality/survival
Primary endpoint: correction rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ductus Arteriosus Closure/Constriction Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in bone material strength in the tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: changes in symptoms related to cancer and chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility (Proportion of patients treated according to the protocol)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: recurrent stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful initial intubation attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to reach Total Energy Expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time for complete regression of pinprick spinal analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to being street ready
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the metformin concentration curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the glucose curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of AZD4877
Endpoint domain: Adverse events/effects
Primary endpoint: End of season depression-free rate
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of Asthma COPD overlap
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hospitalization rate in COVID-19 TX
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline in Gait variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel Movement Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Procedure Safety
Endpoint domain: Adverse events/effects
Primary endpoint: AUCtau of NE and EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of NE and EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of NE and EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of NE and EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Oral CEP-9722
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to CD4+ cell count <350 cells/mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Emergence of documented CDC-defined AIDS-defining illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Start of ART
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Exhaled Nitric Oxide (eNO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Subjects With 1 or More Culture-Verified Acute VVC Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Change in WHO weight-for-height percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of GIT anomalies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality of Life of patients and spouses
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disability of patients and spouses
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Biaxial stress-stretch curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Axial force and diameter curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reaction force curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 2-hr postprandial glucose excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of cases with detectable mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total insulin doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Basal/bolus ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of new diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor Growth Assessment by X-ray/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Functional fitness components
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Urticaria Activity Score (UAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Teriflunomide Concentrations at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weekly average abdominal pain severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in FDG-PET imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress state score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Size of mature follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Hip Disability and Osteoarthritis Outcome Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in SF-12v2 Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Minimal Residual Disease Identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: thickness of the masseter muscle during maximum clenching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: morbidity of hematological adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: morbidity of diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: perioperative changes of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of microembolic signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Operative room time delays
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: iDFS
Endpoint domain: Mortality/survival
Primary endpoint: Striatal D2/3 Binding Potential (BPND) Upregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of micronuclei in peripheral lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in HbA1c Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Inpatient Operating Room Debridements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Verified abstinence from cocaine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of infliximab anti-drug antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Gingival/Periodontal Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral blood ascorbic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Foveal depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optic cup area and depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microcirculation in the digital area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of a combined exercise protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from Baseline Range of Motion Degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Augmentation thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of everolimus and vatalanib
Endpoint domain: Adverse events/effects
Primary endpoint: Therapeutic antitumor activity of everolimus and vatalanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recommended phase II dose (RP2D) of everolimus and vatalanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Assessment of Solar Lentigo and Nevus zygomaticus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Attachment Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically-driven reintervention rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Level of Consciousness (LoC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Muscle thicknesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Median Nerve depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Forearm Perimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forearm Longitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response to insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dysglycemia or diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Florbetapir PET Scan Standard Uptake Value Ratio (SUVr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Reported Xerostomia Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of patients with biomarkers indicating early response to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients responding to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of the NeoRehab Bundle on Motor Performance Using the Test of Infant Motor Performance (TIMP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of the NeoRehab Bundle on Neurologic Function as Assessed by the Hammersmith Infant Neurological Examination (HINE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Abnormal General Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment Area Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Donor Skin Area to Treatment Area Expansion Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of cytokines and chemokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Treatment Acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants who complete 4-month follow-up assessments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: disability due to migraine
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Biodistribution of [18F]FP-R01-MG-F2 (%ID/g)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution of [18F]FP-R01-MG-F2 (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosimetry of [18F]FP-R01-MG-F2 (rem/mCi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosimetry of [18F]FP-R01-MG-F2 (mSv/MBq)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Ocular Tolerability Score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BCVA Score From Baseline Averaged Over Weeks 60 and 64
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children Somatic Symptoms Inventory
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Crying Time Per 24 Hour Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes